FDA Rare Pediatric Disease Designation (RPD)
RareMoon has secured over 20% of all FDA Rare Pediatric Designations.
The FDA's Rare Pediatric Disease (RPD) designation is designed to incentivize the development of therapies for serious or life-threatening conditions affecting individuals under the age of 18. Upon product approval, RPD designation qualifies sponsors for a Priority Review Voucher (PRV), a highly valuable, transferable asset that can expedite another pipeline program or be monetized through transfer to another sponsor.
With a nearly 100% success rate, RareMoon excels in securing RPD designations, frequently in tandem with Orphan Drug Designation (ODD) and often during the preclinical stage of a program development. Services include designation eligibility assessment, authoring, review by subject-matter experts, document reconciliation, and submission.
Services Include:
- Feasibility Assessments and regulatory eligibility analysis
- Author, format, and Quality Control (QC)
- Strategic reviews of client-prepared drafts and rationales
- Guidance on FDA engagement strategy and timing
- Submission
- Post-submission support and FDA response preparation
Disclaimer (Updated February 2026)
Congress has reauthorized the RPD PRV program. In February 2026, the President signed a federal spending bill that includes reauthorization of the RPD PRV program; the Mikaela Naylon Give Kids a Chance Act, restoring the FDA's authority to award RPD PRVs through September 30, 2029.
Key updates under the reauthorized program include:
- Extension of Authority: The legislative change amends Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act to extend the FDA's statutory authority to issue rare pediatric disease PRVs through September 30, 2029.
- Removal of Previous Sunset: The reauthorization eliminates the earlier statutory sunset date of December 20, 2024, ensuring the program remains active for the extended period.
- Program Implementation: With the legislation enacted into law, the FDA's rare pediatric disease PRV program is active again, and the Agency may now accept designation requests and award PRVs for qualifying products during the reauthorized time frame.
At this time, the FDA's official guidance and regulatory framework are being updated to reflect the reauthorization, and affected stakeholders should refer to FDA communications for operational details and submission procedures.